Brokerages expect Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) to announce sales of $80,000.00 for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Bellicum Pharmaceuticals’ earnings, with estimates ranging from $30,000.00 to $100,000.00. Bellicum Pharmaceuticals also posted sales of $80,000.00 during the same quarter last year. The business is expected to announce its next earnings results on Monday, March 12th.
On average, analysts expect that Bellicum Pharmaceuticals will report full year sales of $80,000.00 for the current fiscal year, with estimates ranging from $280,000.00 to $400,000.00. For the next year, analysts forecast that the company will report sales of $310,000.00 per share, with estimates ranging from $120,000.00 to $400,000.00. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.03 million. During the same period in the prior year, the business posted ($0.66) earnings per share. The firm’s revenue for the quarter was up 18.2% compared to the same quarter last year.
Shares of Bellicum Pharmaceuticals (NASDAQ BLCM) traded down $0.19 on Friday, hitting $7.80. 1,036,259 shares of the stock traded hands, compared to its average volume of 489,648. Bellicum Pharmaceuticals has a 12 month low of $7.41 and a 12 month high of $15.55. The company has a market capitalization of $253.00, a PE ratio of -2.61 and a beta of 1.18. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.08 and a quick ratio of 6.08.
In related news, CFO Alan A. Musso sold 17,117 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $9.33, for a total value of $159,701.61. Following the transaction, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at $294,688.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $8.20, for a total transaction of $7,222,027.00. The disclosure for this sale can be found here. Insiders sold 1,165,145 shares of company stock worth $9,696,662 over the last three months. 18.77% of the stock is currently owned by insiders.
A number of large investors have recently made changes to their positions in BLCM. Point72 Asset Management L.P. bought a new position in Bellicum Pharmaceuticals in the third quarter valued at approximately $4,723,000. Vanguard Group Inc. grew its stake in shares of Bellicum Pharmaceuticals by 13.6% during the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock worth $14,092,000 after buying an additional 144,854 shares during the last quarter. Numeric Investors LLC bought a new stake in shares of Bellicum Pharmaceuticals during the second quarter worth $1,137,000. Goldman Sachs Group Inc. grew its stake in shares of Bellicum Pharmaceuticals by 223.5% during the second quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock worth $1,612,000 after buying an additional 95,336 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Bellicum Pharmaceuticals by 29.5% during the second quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock worth $3,989,000 after buying an additional 77,760 shares during the last quarter. 55.28% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “$80,000.00 in Sales Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/20/80000-00-in-sales-expected-for-bellicum-pharmaceuticals-inc-blcm-this-quarter.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.